| | | Choosing the right partner to deliver decentralised clinical trials is crucial. ICON has the experience and expertise to overcome the challenges in patient recruitment and retention to deliver study success. Explore ICON's DCT capabilities. 
|
|
Today’s Big News Oct 2, 2023 |
| October 16-18, 2023 | Boston, MA This event is designed to bring together leaders and executives within the biotech and life sciences industry to discuss the most pressing challenges around product development, bringing an asset to market and building successful companies in this complex landscape. LAST CHANCE TO REGISTER! 
|
|
| | By Ayla Ellison The Fierce 50 special report shines a spotlight on 50 remarkable individuals and organizations reshaping biopharma and healthcare. Explore their profiles across five categories, each representing a pivotal aspect of the industry. |
|
|
|
| By Nick Paul Taylor Discoveries that enabled mRNA vaccines against COVID-19 have landed two scientists a Nobel Prize. The Nobel Assembly awarded Katalin Karikó and Drew Weissman the prize for their work on nucleoside base modifications, which underpinned the Moderna and Pfizer-BioNTech vaccines that changed the course of the pandemic. |
| By James Waldron With VC firms Forbion and BioGeneration Ventures announcing their largest biopharma funds to date this year, how is investor interest in European biotechs holding up? |
| By Annalee Armstrong After a merger with MEI Pharma was unsuccessful, Infinity Pharma has filed for bankruptcy, just as executives had warned when the deal fell through. |
| By Gabrielle Masson Novartis’ investigational oral factor B inhibitor has hit its early target in a phase 3 kidney disorder trial, a success that has the pharma readying to submit a request for fast-track FDA approval next year. |
| By Max Bayer Abivax and Lexeo are the latest biotechs to go public, each disclosing their plans on Friday. The decisions come as other companies mull whether Wall Street is the best route for more cash. |
| By Fraiser Kansteiner The FDA has rejected Lilly’s investigational atopic dermatitis treatment lebrikizumab over findings uncovered during the inspection of a third-party contract manufacturing organization. |
| By Nick Paul Taylor Syndax Pharmaceuticals has stopped a pivotal cancer clinical trial early for efficacy—which sent the biotech's share price down 9%. The negative reaction to superficially positive news reflects the failure to live up to efficacy expectations and the emergence of a safety concern. |
| By Annalee Armstrong Pneumagen’s intranasal flu antiviral has stood up to the challenge—a human challenge study, that is. The Scottish company has found that Neumifil reduced the symptomatic infection rate and severity of viral respiratory tract infections during a phase 2 proof-of-concept trial. |
| By Annalee Armstrong A few weeks after a second company walked away from Syros Pharmaceuticals, the biotech is laying off 35% of staff and sharpening focus on a medicine for higher-risk myelodysplastic syndrome and acute myeloid leukemia. |
| By Helen Floersh Scientists have found a new piece in the puzzle that explains why B cells self-react in autoimmune disease—and, with it, a potential new treatment strategy. |
| By Andrea Park Nearly a year after Medtronic announced its intent to spin out its patient monitoring and respiratory interventions divisions, the business units have reportedly found a buyer. |
| By Eric Sagonowsky The exact launch timing of the biosimilar remains unclear, but Roche said it expects competition to kick off in the second half of 2023. |
| By Conor Hale While the act of parsing DNA for an inherited, cancer-linked mutation is nothing new, the scale offered by Invitae’s test has defined a new product category going forward, the agency said. |
| Fierce podcasts Don’t miss an episode |
| | In this episode of "The Top Line," Fierce Pharma's Eric Sagonowksy talks with Pam Cheng, the AstraZeneca executive who is playing a key role in driving the company's sustainability ambitions. |
|
|---|
|
|
| October 16-17 | Boston, MA LAST CHANCE! Enhance commercial success by optimizing the pipeline and making prioritization decisions. Don't miss this one of a kind event, Register today! 
|
|
| Webinar Embark on an in-depth journey through the pivotal Make-Test-Decide Workflow, where collaboration and data-driven decisions play a paramount role in the intricate landscape of drug discovery. Watch now to learn how cloud implementation fosters accessibility and collaboration, revolutionizing research across locations and companies. Sponsored by: Revvity Signals |
| eBook Learn how to get better results from suboptimal biospecimens for NGS and protein analysis. Sponsored by: Covaris |
| Whitepaper Economic and regulatory factors are making biopharma supply chains more complex in the EU. This paper explores strategies that biopharma companies can use to better manage complexity, cost, and risk. Presented by: AIM, the supply chain leader for life science entrants and midsize life science companies |
| Whitepaper From Assay Development Through Large Molecule Development. Streamline your R&D workflows and gain valuable insights with our Biology Solutions Brochure. Download now to discover how to control your laboratory workflows across various assay techniques, modalities, and data types. Sponsored by: Revvity Signals |
| eBook Emulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
| Whitepaper Learn more about how you can improve the productivity of your research and manufacturing operations and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
| Whitepaper Learn how outsourcing the buffer preparation can reallocate resources to support core activities of your bioprocess production. Sponsored by: Thermo Fisher Scientific |
| Whitepaper From trial site feasibility and patient populations to data analysis, generative AI has the potential to revolutionize drug discovery and clinical trial recruitment at both the therapeutic area and indication level. Sponsored by: H1 |
| Whitepaper Learn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
| Whitepaper By 2030, the global demand for biologics is projected to grow at a CAGR of 8.7% and the challenges, risks, and costs of bringing large molecule products to market are growing exponentially. Sponsored by: ThermoFisher Scientific |
| | |
|
